CIBC Private Wealth Group
MTNB icon

CIBC Private Wealth Group’s Matinas BioPharma MTNB Stock Holding History

CIBC Private Wealth Group’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-12,000
Closed -$816K – 1040
2020
Q4 		$816K Hold
12,000
– – ﹤0.01% 671
2020
Q3 		$460K Hold
12,000
– – ﹤0.01% 695
2020
Q2 		$464K Buy
+12,000
New +$460K ﹤0.01% 535
2020
Q1 		– Sell
-4,000
Closed -$454K – 901
2019
Q4 		$454K Buy
+4,000
New +$232K ﹤0.01% 721

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

CIBC Private Wealth Group's MTNB Position: Q1 2021 in Review

CIBC Private Wealth Group sold out of Matinas BioPharma (MTNB) in Q1 2021, closing a stake of 12,000 shares — an estimated $816K sold.

CIBC Private Wealth Group first reported a position in MTNB in Q4 2019 and held it in 4 quarters. The position peaked at $816K in Q4 2020. 80 funds tracked by Wall St. Rank hold MTNB as of Q1 2021.

  • CIBC Private Wealth Group reported no remaining Matinas BioPharma position as of Q1 2021 after selling out during the quarter.
  • CIBC Private Wealth Group sold 12,000 Matinas BioPharma shares in Q1 2021, an estimated $816K.
  • CIBC Private Wealth Group first reported a position in Matinas BioPharma in Q4 2019 and held it in 4 quarters.
  • CIBC Private Wealth Group's Matinas BioPharma position peaked at $816K in Q4 2020.
  • 80 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2021.

Based on CIBC Private Wealth Group's 13F filing for Q1 2021, filed 12 May 2021.